Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

DYT-TUBB4A (DYT4 dystonia): New Genetic and Clinical Observations in three Families
Movement Disorders
P15 - Poster Session 15 (12:00 PM-1:00 PM)
3-012

To better delineate the clinical picture of TUBB4A mutations and present three new likely pathogenic variants.

DYT-TUBB4A, formerly known as DYT4, has only been described in one large family and two individual cases. The clinical picture highlighted in the original family comprises laryngeal and cervical dystonia extending to generalized dystonia, plus a “hobby horse” gait disorder. The variant identified as causative in the original family was a heterozygous missense mutation R2G in exon 1 of the TUBB4Agene.

We screened three families including a total of nine definitely affected members with a clinical picture resembling the original description. 

Three novel variants in the TUBB4A gene have been identified: D295N, R46M, Q424H. In silicomodeling showed that all variants have similar characteristics to R2G. The variants segregate with the disease in 2 of the families. All three variants would be classified as likely pathogenic. The clinical picture particularly included laryngeal dystonia (often the site of onset), associated with cervical and upper limb dystonia and frequent generalization. Laryngeal dystonia was extremely prevalent (>90%) both in the original cases and in this case series. The “hobby horse” gait was not demonstrated in this case series. 

Laryngeal dystonia in TUBB4A mutations must be highlighted. Nevertheless, TUBB4A mutations remain an exceedingly rare cause of laryngeal or other isolated dystonia.

Authors/Disclosures
Julien F. Bally, MD (CHUV Centre Hospitalier Universitaire Vaudois)
PRESENTER
No disclosure on file
Sarah Camargos, MD (Neurology Movement Disorder Clinic,FD) No disclosure on file
Laurie J. Ozelius, PhD The institution of Dr. Ozelius has received research support from NIH. Dr. Ozelius has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
Anthony E. Lang, MD, FÂé¶¹´«Ã½Ó³»­ (Toronto Western Hospital) Dr. Lang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AbbVie, Amylyx, Aprinoia, Biogen, BioAdvance, Biohaven, BioVie, BlueRock, BMS, Denali, Janssen, Lilly, Pharma 2B, Sun Pharma, and UCB. Dr. Lang has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for medicolegal cases related to paraquat. The institution of Dr. Lang has received research support from AbbVie. Dr. Lang has received intellectual property interests from a discovery or technology relating to health care. Dr. Lang has received publishing royalties from a publication relating to health care.